IDH1 and acute myeloid leukemia: The IDH2 inhibitor enasidenib and the IDH1 inhibitor ivosidenib received FDA approval in 2017 and 2018 for selected patients with IDH2- and IDH1-mutated relapsed and refractory (R/R) AML, respectively.